ICL:
The Complete 2026 Guide

What ICL is and how it works

An ICL (Implantable Collamer Lens) is a soft, flexible lens implanted inside the eye to correct refractive error. Unlike LASIK, which reshapes the cornea, ICL adds an optical element behind the iris that neutralizes refractive error without altering any existing eye structure.

The lens itself is made of collamer, a proprietary material combining collagen and a hydrophilic polymer. It’s designed to be biocompatible with the eye’s natural chemistry and to remain optically clear long-term. STAAR Surgical, headquartered in California, is the primary global manufacturer. Their EVO Visian ICL is the current-generation lens installed at credentialed refractive centers worldwide.

The lens sits in the posterior chamber — the space behind the iris and in front of the natural crystalline lens. It doesn’t touch the cornea, the iris, or the natural lens under normal conditions. Natural aqueous humor (the fluid that fills the front of the eye) flows around and through the lens via a central port in the EVO design.

The main indications for ICL

• High myopia beyond LASIK range: LASIK becomes less predictable at prescriptions beyond about -8D and is generally not recommended beyond -10 to -12D depending on corneal thickness. ICL corrects up to about -20D of myopia in a single lens.
• Thin corneas that rule out LASIK: LASIK requires adequate corneal thickness (typically at least 500 microns pre-op, with residual bed above 250-280 microns post-op depending on surgeon). Patients with thinner corneas are often better served by ICL.
• Keratoconus-suspect findings: Any topographic finding suggesting subclinical keratoconus is a contraindication to LASIK because the flap-creation step further weakens the cornea. ICL avoids the cornea entirely.
• Significant baseline dry eye: LASIK typically worsens dry eye during recovery. ICL doesn’t disrupt corneal nerves in the same way and is often the more appropriate procedure for dry-eye-prone patients.
• Very active or contact sports lifestyle: ICL avoids the LASIK flap, eliminating the small long-term risk of flap displacement from ocular trauma.
• Patient preference for reversibility: Some patients strongly value the reversibility of ICL, particularly younger patients who anticipate significant visual demand changes over their lifetime.

Cost across five destinations

Here’s 2026 EVO Visian ICL per-eye pricing at ISRS-affiliated hospital-adjacent clinics across five destinations plus the US baseline.

For bilateral EVO ICL at Colombia or Turkey pricing, budget $7,600-$8,200 total surgical cost. US pricing for the same case runs $15,000-$18,000. After flights, hotel, and follow-up planning, most US patients net $5,000-$8,000 savings on the trip.

ICL vs LASIK: the honest comparison

ICL and LASIK are both refractive procedures aimed at reducing or eliminating glasses and contact lens dependence. They operate on different parts of the eye with different risk profiles and different appropriate patient populations.

Where LASIK wins

• Lower cost (roughly one-third of ICL pricing).
• Longer published track record (LASIK has been done since 1990; EVO ICL since 2011, older ICL designs since 1997).
• Extraocular procedure — lower absolute risk profile.
• Slightly faster same-day visual recovery.
• Well-established enhancement protocols.

Where ICL wins

• Extended prescription range (corrects up to -20D myopia; LASIK typically capped at -8 to -10D).
• No corneal tissue removal — preserves the cornea entirely.
• Reversible — the lens can be removed if needed.
• Better fit for thin corneas, keratoconus-suspect eyes, and significant dry eye.
• Less impact on baseline dry-eye status.
• Preserves accommodation for patients under 40.
• Doesn’t affect the cornea’s ability to undergo LASIK/PRK later if needed.

Comparative visual: ICL vs LASIK on key dimensions

See ICL vs LASIK: The Detailed Comparison for the full head-to-head breakdown including candidacy tables and specific-scenario recommendations.

The ICL workup: what to expect

ICL workup is more involved than LASIK workup because ICL is intraocular surgery. The lens must be sized to fit your specific eye anatomy, and multiple anatomical measurements must be within specific ranges for ICL to be appropriate.

Standard ICL pre-op workup includes:

• Cycloplegic refraction: Dilated refraction to establish precise refractive target.
• Corneal topography and tomography: Pentacam or Galilei imaging to screen for keratoconus and confirm ICL is appropriate rather than LASIK.
• Anterior chamber depth (ACD) measurement: ICL requires minimum ACD of 2.8mm typically. Shallower chambers rule out ICL.
• Anterior segment OCT: Detailed imaging of the anterior chamber for sizing calculations.
• White-to-white (WTW) measurement: Used with other measurements to select ICL size.
• Sulcus-to-sulcus measurement (UBM): Ultrasound biomicroscopy of the ciliary sulcus. Some surgeons rely on this for sizing rather than WTW.
• Endothelial cell count: Baseline corneal endothelial health assessment. ICL patients should have adequate endothelial cell density (typically above 2,000 cells/mm²).
• Dilated fundus exam: Screening for retinal issues, particularly important in high myopes who have elevated retinal detachment risk.
• Intraocular pressure (IOP) and gonioscopy: Screening for glaucoma or narrow-angle glaucoma risk.

EVO ICL: what changed

EVO Visian ICL is STAAR Surgical’s current-generation lens, in widespread use globally and FDA-approved in the US since 2022. The main difference from older-generation ICL is the central port: a small hole in the center of the lens that allows natural aqueous humor flow through the lens.

Practical implications of the central port:

• No pre-op iridotomies required: Older ICL designs required two peripheral iridotomies (small openings in the iris) created with a YAG laser 1-2 weeks before ICL surgery. These allowed aqueous flow around the lens edge. EVO ICL eliminates this step, simplifying the pre-op process.
• Reduced pupillary block risk: The central port maintains aqueous flow even in the rare cases where positioning issues might otherwise cause pupillary block glaucoma.
• Updated material characteristics: The EVO lens material has been refined for improved biocompatibility and reduced anterior subcapsular cataract risk compared to older designs.

See EVO ICL: The Central-Port Lens Explained for the detailed platform comparison.

Destination comparison for ICL candidates

ICL destination factors: STAAR ICL platform breadth (some clinics primarily install EVO; others carry the full range including Toric variants), anterior segment workup depth (ACD measurement, OCT, endothelial cell count), cataract-adjacent expertise (ICL is intraocular surgery; surgeons should have strong cataract surgery foundation), and credentialing depth.

Colombia profiles strongly for ICL candidates. Hospital-affiliated Bogotá and Medellín centers have both the ICL platform investment (full STAAR EVO ICL and Toric range) and the cataract-adjacent surgical foundation that ICL requires. Anterior segment workup depth includes Pentacam, anterior segment OCT, and specular microscopy at credentialed centers. Same time zone as US Eastern makes follow-up practical.

Turkey is a global leader in ICL adoption and has arguably the deepest case volume outside the US and China. Istanbul centers particularly have strong EVO ICL programs. Flight length (11-13 hours) is a real trade-off for US patients.

Mexico offers the shortest flight for many US patients. ICL availability is strongest at Mexico City and Guadalajara hospital-affiliated centers.

Thailand has strong ICL infrastructure and platform breadth. Better fit for patients based in Asia or the Pacific.

Costa Rica offers reasonable proximity for US East Coast patients with good English fluency. ICL case volume is lower than Colombia, Turkey, or Mexico.

The ICL trip: logistics

Standard ICL trip (5 days)

• Day 1 (Wednesday): Arrive. Rest, adjust.
• Day 2 (Thursday): Pre-op consult and comprehensive workup. Contact lenses out for at least 1 week prior if soft, 3-4 weeks if rigid gas permeable.
• Day 3 (Friday): ICL surgery in first eye. Rest afternoon.
• Day 4 (Saturday): Day-one follow-up on first eye. Second-eye ICL surgery (or wait for Monday depending on surgeon preference).
• Day 5-6: Follow-up on second eye. Return flight home.

Split-visit ICL trip

Some patients prefer to split the ICL trip: one shorter visit for pre-op workup and ICL sizing, then a second visit 2-4 weeks later for surgery once the lens is manufactured and shipped. STAAR ICL is custom-manufactured to the specific size and power calculated during workup; typical manufacturing time is 2-4 weeks. Split visits work well for patients who want time to consider results after workup or need to coordinate work schedules.

Long-term considerations for ICL patients

Cataract surgery down the line

ICL is not a substitute for cataract surgery. When cataract eventually develops (typically age 65-75 for most patients), cataract surgery is still needed. ICL is removed as part of cataract surgery, and an IOL is implanted in the natural lens capsule — standard cataract surgery. The presence of an ICL doesn’t complicate future cataract surgery meaningfully; experienced cataract surgeons handle ICL removal as a routine step.

Endothelial cell monitoring

Long-term endothelial cell count monitoring is a standard part of ICL follow-up. The corneal endothelium (single cell layer on the inside of the cornea) doesn’t regenerate; any procedure inside the anterior chamber causes small permanent cell loss. Baseline and follow-up specular microscopy at years 1, 3, 5, and beyond confirms endothelial health remains adequate.

Vault monitoring

Vault is the distance between the posterior surface of the ICL and the anterior surface of the natural lens. Ideal vault is 250-750 microns. Too little vault (approaching zero) risks anterior subcapsular cataract. Too much vault risks pigment dispersion or elevated IOP. Anterior segment OCT at follow-up visits monitors vault status. Vault adjustment through lens exchange is rare but possible if needed.

Refractive stability

Once ICL is positioned correctly and the eye has healed (typically 2-4 weeks), the refractive result is stable long-term. Unlike LASIK, which has a small long-term regression rate, ICL doesn’t regress because the optical element (the lens) is stable. Natural refractive changes (progressing presbyopia, cataract development) affect ICL patients the same as anyone else.

The decision framework

By the end of your workup, you should have clear answers to these questions:

1. What is my exact refractive prescription, and is it within the ICL range?
2. What is my corneal thickness and topography, and does it favor ICL over LASIK?
3. What is my anterior chamber depth, and is it adequate for ICL (typically above 2.8mm)?
4. What is my endothelial cell count?
5. What are the specific ICL model, size, and power recommended for my eyes?
6. What is the surgeon’s ICL case volume, and specifically EVO ICL case volume in the past 12 months?
7. What is the surgeon’s protocol for sizing calculation (WTW-based, UBM-based, or both)?
8. What is the plan for long-term follow-up (endothelial cell counts, vault monitoring, refractive checks)?

Answers in writing. ICL is a decision that deserves comprehensive workup depth and specific answers, not general reassurance.

Frequently asked questions